World

Austria sees economic contraction in Q2

Sep 02, 2023

Vienna [Austria], September 2:Austria's gross domestic product (GDP) shrank by 1.1 percent in real terms year on year in the second quarter (Q2) of this year, logging the country's first quarterly economic contraction in the past eight quarters, Statistics Austria said on Friday.
The contraction was mainly due to lackluster performances of the trade and industry sectors, which shrank by 6.7 percent and 2 percent year on year, respectively, according to a press release from the institution.
Director-General of Statistics Austria Tobias Thomas said Austria's economic growth has weakened since the second half of 2022, and its economy "weakens and shrinks in spring 2023 for the first time in eight quarters."
While Austria's inflation has steadily declined to 7.5 percent in August from a peak of over 10 percent in late 2022, it remained high compared to other countries in the eurozone, Statistics Austria said.
The Austrian Institute of Economic Research (WIFO) on Thursday reported continued decline in business assessments of the country's economy, with its Business Climate Index dropping to minus 8.9 points in August from minus 5.2 points in the previous month.
"Assessments of the current situation declined across all sectors and were deeply in negative territory, especially in manufacturing," the institute said in a statement. "Economic expectations also deteriorated further, signaling a pessimistic economic outlook."
Source: Xinhua

More news

Concept Medical Announces Successful SIRONA Trial Results, Demonstrating Sirolimus-Coated Balloon as a Promising Alternative for PAD Treatment

Tampa (Florida) [US], January 7: Concept Medical Inc., a global leader in innovative drug-delivery technology, proudly reports positive outcomes from the SIRONA (Head-to-Head Comparison of SIROlimus versus Paclitaxel Drug-Eluting BallooNAngioplasty in the Femoropopliteal Artery) RCT, which show that its sirolimus-coated balloons (SCB) (MagicTouch -PTA) provide patency and functional benefits on par with paclitaxel-coated balloons for patients suffering from peripheral artery disease (PAD). The 1-year data was presented by Principal Investigator Prof. Ulf Teichgraber at the TCT USA 2024 conference in a Late-Breaking Clinical Trials Session (LBCT). Coverage by TCTMD has highlighted these findings, underscoring sirolimus-based therapy as a viable new option in femoropopliteal interventions.

Jan 07, 2025